|Referral date||01 November 2008|
The Department of Health asked the Institute to conduct an appraisal of bevacizumab for the treatment of recurrent glioblastoma and to provide guidance on its use to the NHS in England and Wales.
The Institute has noted that the Committee for Medicinal Products for Human Use (CHMP) recently adopted a negative opinion on extending the current indication of bevacizumab (Avastin) to include use in patients with recurrent glioblastoma. For further information please click on the following link: http://www.emea.europa.eu/pdfs/human/opinion/Avastin_Q&A_74620809en.pdf
NICE has therefore decided to remove this appraisal from its current work programme.
As this topic has been referred to the Institute we will continue to monitor any development and will update this webpage if the situation changes.
|Closing date for invited submissions / evidence submission:||TBC|
|1st appraisal committee meeting:||TBC|
|2nd appraisal committee meeting||TBC|
For further information on our processes and methods, please see our CHTE processes and methods manual